LANA2 Antibody (CM-A807) [FITC]

• Reactivity: Hu, Mu, V-Vi
• Applications: WB, ELISA, ICC/IF, IHC, IP, KO
• Clone: CM-A807
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: FITC

LANA2 Antibody (CM-A807) [FITC] Summary

• Immunogen: Recombinant LANA2 fusion protein.
• Localization: Nuclear
• Specificity: This is specific for KSHV LANA2 (residues 143-310 epitope recognition).
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • ELISA
  • Immunocytochemistry/ Immunofluorescence
  • Immunohistochemistry
  • Immunohistochemistry-Frozen
  • Immunohistochemistry-Paraffin
  • Immunoprecipitation
  • Knockout Validated
  • Western Blot
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Reactivity Notes

Reacts with viral LANA2 protein and shows no cross-reactivity to cellular proteins. Also reacts with human and mouse viral KSHV proteins.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: PBS
• Preservative: 0.05% Sodium Azide
• Purity: Protein G purified

Alternate Names for LANA2 Antibody (CM-A807) [FITC]

• LANA 2
• LANA-2
• Latency-associated nuclear antigen 2
• vIRF 3
• vIRF3
• vIRF-3

Background

LANA2 (latency-associated nuclear antigen 2; also known as viral interferon regulatory factor 3) is a Kaposi's sarcoma-associated herpesvirus (KSHV) latent protein which is encoded by ORFK10.5 and is exclusively expressed by virus infected B- cells. LANA2 has been shown to be critical in KSHV-mediated tumorigenesis as it inhibits p53 function, dsRNA-activated protein kinase R (PKR)-dependent apoptosis, nuclear factor kB activity, interferon regulatory factor 7-mediated interferon signal transduction and virus-mediated transcriptional activation of the alpha-interferon promoter. LANA2 stabilizes and triggers the induction of HIF-1alpha's transcriptional activity and disrupts PODs (PML oncogenic domains). Moreover, LANA2 has been shown to be required for the survival of primary effusion lymphoma (PEL) cells infected with KSHV alone or dually infected by Epstein-Barr virus (EBV) and KSHV, wherein it shows nuclear and cytoplasmic expression.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.